Immune and cardiovascular system signaling proteins

The term Immune and cardiovascular system signaling proteins refers to a broad and heterogeneous functional category of molecules that facilitate communication between the immune and cardiovascular systems, a field increasingly recognized as cardio-immunology (Swirski & Nahrendorf, 2018, Science). This group is not a single therapeutic target but encompasses various cytokines, chemokines, and receptors that regulate vascular tone, leukocyte recruitment, and the inflammatory response to cardiac injury. These proteins are central to the pathogenesis of chronic conditions such as atherosclerosis and heart failure, where maladaptive immune signaling drives tissue remodeling and vascular dysfunction (Ridker et al., 2017, NEJM). Because this classification includes a wide array of distinct molecular entities, it cannot be addressed by a single pharmacological agent. Instead, drug development focuses on specific members within this group, such as Interleukin-1 beta or Tumor Necrosis Factor, to modulate specific pathways while attempting to preserve essential physiological functions. Consequently, this entry is considered a high-level descriptive grouping rather than a discrete, druggable molecular target.

Other names

Cardio-immune signaling moleculesImmune-cardiovascular crosstalk proteinsCardiovascular-immune system mediators

Not applicable as this is a broad functional category of proteins rather than a specific molecular target.